▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Motley Fool Staff

the_motley_fool

Recent Articles by Motley Fool Staff

Nov 25, 2016 by Motley Fool Staff

How to Calculate the Quota Rent on Supply and Demand

Measuring the inefficiencies created from import quotas.

Feb 10, 2016 by Motley Fool Staff

Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know

The biopharmaceutical has some obstacles to overcome if it's going to deliver in 2016.

Feb 10, 2016 by Motley Fool Staff

Why Do Stocks Get Added and Removed From the S&P 500?

A look at the five traits companies need to have to enter the Standard & Poor's 500 index, and stay there.

Feb 10, 2016 by Motley Fool Staff

What to Expect from Gilead Sciences, Inc.'s New CEO

The company has a strong history of both returning money to shareholders and investing in the future and its new boss is expected to continue that.

Feb 9, 2016 by Motley Fool Staff

Why Do Share Prices Go Up and Down?

How stock prices are set, why they change, and how they're affected by shifts in the global economy.

Feb 9, 2016 by Motley Fool Staff

One Metric You Need to Know to Make Sense of a Stock's Price

Why do Amazon’s shares seem so expensive, while GoPro’s appear to be so cheap?

Feb 9, 2016 by Motley Fool Staff

Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck

Merck's Zepatier poses a new challenge to Gilead's best-selling drug, but maybe it's not as threatening as some think.

Dec 23, 2016 by Motley Fool Staff

How to Calculate the Weighted Average Trade Price

If you bought a different number of shares with each trade, a simple average of the prices won't be accurate.

Feb 8, 2016 by Motley Fool Staff

Is Chipotle Mexican Grill, Inc.’s Health Scare Going to Permanently Scar the Company?

The crisis may be over, but how long the effects linger remains to be seen.

Feb 8, 2016 by Motley Fool Staff

Is Peer-to-Peer Lending a Good Investment?

How P2P sites work, who’s behind them, and whether or not you should sink some money into them.

Feb 8, 2016 by Motley Fool Staff

Will Gilead Sciences, Inc. Continue to Dominate HIV Treatment?

The launch of next generation therapies could help Gilead Sciences retain its market share.

Feb 8, 2016 by Motley Fool Staff

Investing Advice, and a Look Into the Future With David Gardner

Motley Fool co-founder David Gardner stops by to answer your questions about investing in tech. He also makes some predictions.

Feb 7, 2016 by Motley Fool Staff

Is Chipotle Mexican Grill Inc. Really Recovering From its Food Safety Issues?

The CDC says the E.coli problem at Chipotle is probably over. But are you going back for a burrito bowl?

Feb 7, 2016 by Motley Fool Staff

1 Energy Company That Has High Hopes for 2016

The Industry Focus energy team takes a look at Core Labs' recent earnings and its CEO's statement that 2016 will be the pivotal point for oil prices.

Feb 6, 2016 by Motley Fool Staff

How Does the Low Price of Oil Affect Banks?

Not all banks are created equal when it comes to energy exposure.

Feb 5, 2016 by Motley Fool Staff

One Retailer that Shocked Analysts with Fantastic 2015 Growth

First it was Coach, and now another luxury retailer's stock is surging after handily beating analysts' estimates.

Feb 5, 2016 by Motley Fool Staff

Why Isn’t Johnson & Johnson Making More Acquisitions?

The healthcare giant has plenty of cash on hand, but it's clearly waiting for the right opportunity to spend it.

Feb 3, 2016 by Motley Fool Staff

Apple Inc. Doesn't Spill the Beans on Apple Watch Sales

Perhaps being cagey about Apple Watch sales is part of a strategy.

Feb 3, 2016 by Motley Fool Staff

Reading Between the Lines of Apple Inc.’s Conference Call Data

Investors who take the time to listen to or read a transcript of a company's earnings conference call tend to get rewarded with a few juicy nuggets of information. The Motley Fool’s Dylan Lewis and Sean O’Reilly share one they found.

Feb 3, 2016 by Motley Fool Staff

One Big Threat to Johnson & Johnson's Future

The expiring patents on top-selling Remicade could put a big dent in the company's top line.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services